Acetazolamide Per os for Decompensation of Heart Failure

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually. Acute decompensation of CHF is understood as a rapid increase in the severity of clinical manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial hypotension), which caused urgent medical treatment and emergency hospitalization in a patient already suffering from CHF. Decompensation of CHF requires intensification of treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in addition to standard therapy helps to reduce edematous syndrome.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Men or women aged 18 years and older

• Decompensated CHF NYHA II-IV, which required intravenous administration of diuretics

• Any injection fraction of left ventricle\*

• Signed informed consent to participate in the study.

⁃ in patients with LV LV ≥ 50%: the presence of structural changes of the heart# (left ventricular myocardial hypertrophy, enlargement of the left atrium) and/or diastolic dysfunction# and/or increased levels of BNP or NT-proBNP (BNP \> 400 pg/ml or NT-proBNP \> 450 pg/ml in persons younger 50 years old; \> 900 pg/l in persons 51-75 years old; \> 1800 pg/ml older than 75 years) #.

‣ criteria according to clinical guidelines 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083

Locations
Other Locations
Russian Federation
Samara state medical university
RECRUITING
Samara
Contact Information
Primary
Dmitriy Duplyakov, MD
Duplyakov@yahoo.com
89277297273
Backup
Olesya Rubanenko, MD
olesya.rubanenko@gmail.com
89371887780
Time Frame
Start Date: 2023-05-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 400
Treatments
Experimental: a group with the use of acetazolamide
acetazolamide is prescribed at a dose of 250 mg 3 times a day
No_intervention: a group of standart therapy
standart therapy includes main and additional medicine for treatment of chronic heart failure
Sponsors
Leads: Samara State Medical University

This content was sourced from clinicaltrials.gov